ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years
Fong Cheng Pan
Matched on ORCID iD 0000-0002-9393-6574; OpenAlex author ID A5030066005. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 5
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Co-author DOI 10.1016/j.devcel.2026.04.012↗
- A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Last author DOI 10.1016/j.stem.2023.11.011↗
- Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
- The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.7554/elife.07125↗
- Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2012.10.025↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Steven D Leach · 3 shared papers, 2020–2026 · strength 0.46
- Paper Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. DOI 10.1016/j.devcel.2026.04.012↗
- Paper A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. DOI 10.1016/j.stem.2023.11.011↗
- Paper Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. DOI 10.1016/j.ccell.2020.05.010↗
- Rohit Chandwani · 2 shared papers, 2024–2026 · strength 0.39
- Gökçe Aşkan · 2 shared papers, 2020–2026 · strength 0.27
- Aslihan Yavas · 1 shared paper, 2026 · strength 0.20
- Adrien Grimont · 1 shared paper, 2026 · strength 0.20
- Xian Zhang · 1 shared paper, 2026 · strength 0.20
- Danwei Huangfu · 1 shared paper, 2026 · strength 0.20
- Jen Jen Yeh · 1 shared paper, 2026 · strength 0.20
- Christine A. Iacobuzio–Donahue · 1 shared paper, 2026 · strength 0.20
- Xiaohua Duan · 1 shared paper, 2024 · strength 0.18
- John P. Morris · 2 shared papers, 2012–2020 · strength 0.10
- Chun‐Hao Pan · 1 shared paper, 2020 · strength 0.07
- Peter J. Bailey · 1 shared paper, 2020 · strength 0.07
- Scott W. Lowe · 1 shared paper, 2020 · strength 0.07
- Srivatsan Raghavan · 1 shared paper, 2020 · strength 0.07
- Olivera Grbovic-Huezo · 1 shared paper, 2020 · strength 0.07
- Andrew J. Aguirre · 1 shared paper, 2020 · strength 0.07
- Brian Matthew Wolpin · 1 shared paper, 2020 · strength 0.07
- Channing J. Der · 1 shared paper, 2020 · strength 0.07
- G. Aaron Hobbs · 1 shared paper, 2020 · strength 0.07
- Luisa F. Escobar‐Hoyos · 1 shared paper, 2020 · strength 0.07
- David Kuang-Fu Chang · 1 shared paper, 2020 · strength 0.07
- Kenneth Reed Shroyer · 1 shared paper, 2020 · strength 0.07
- Andrew Victor Biankin · 1 shared paper, 2020 · strength 0.07
- Andrea Oeckinghaus · 1 shared paper, 2020 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.